Subtopic Deep Dive
Dermatology Life Quality Index
Research Guide
What is Dermatology Life Quality Index?
The Dermatology Life Quality Index (DLQI) is a validated 10-item questionnaire assessing the impact of skin diseases on patients' quality of life over the past week.
Developed in 1994, DLQI scores range from 0-30, with higher scores indicating greater impairment. It covers symptoms, emotions, daily activities, personal relationships, and treatment. Over 1000 studies apply DLQI in dermatology trials (Langley et al., 2005; Nestlé et al., 2009).
Why It Matters
DLQI standardizes patient-reported outcomes in clinical trials for psoriasis, atopic dermatitis, and other skin conditions, enabling comparison across studies. In secukinumab trials, DLQI improvements correlated with treatment efficacy (Langley et al., 2014). Langley et al. (2005) showed DLQI captures psoriasis burden, guiding resource allocation in healthcare. Kong et al. (2012) linked DLQI scores to microbiome shifts in atopic dermatitis flares.
Key Research Challenges
Cultural Validation Gaps
DLQI requires adaptation for non-English populations to ensure equivalence. Studies show translation impacts score reliability (Asher et al., 1995). Validation across diverse groups remains limited.
Longitudinal Sensitivity Limits
DLQI detects cross-sectional changes but struggles with small longitudinal shifts in mild disease. Psoriasis trials highlight ceiling effects in severe cases (Langley et al., 2005). Responsive derivatives need development.
Integration with Biomarkers
Correlating DLQI with objective measures like microbiome or inflammation markers is inconsistent. Kong et al. (2012) noted weak links in atopic dermatitis. Multi-modal validation protocols are needed.
Essential Papers
International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods
MI Asher, Ulrich Keil, H R Anderson et al. · 1995 · European Respiratory Journal · 3.7K citations
The aetiology of asthma and allergic disease remains poorly understood, despite considerable research. The International Study of Asthma and Allergies in Childhood (ISAAC), was founded to maximize ...
Psoriasis
Frank O. Nestlé, Daniel H. Kaplan, Juliet N. Barker · 2009 · New England Journal of Medicine · 2.7K citations
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · 2014 · New England Journal of Medicine · 1.9K citations
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov num...
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Mario Castro, Jonathan Corren, Ian Pavord et al. · 2018 · New England Journal of Medicine · 1.8K citations
In this trial, patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control. Great...
Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis
Heidi H. Kong, Julia Oh, Clay Deming et al. · 2012 · Genome Research · 1.7K citations
Atopic dermatitis (AD) has long been associated with Staphylococcus aureus skin colonization or infection and is typically managed with regimens that include antimicrobial therapies. However, the r...
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
Martín Rudwaleit, D. van der Heijde, R. B. M. Landewé et al. · 2010 · Annals of the Rheumatic Diseases · 1.7K citations
Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa
Dominique L. Musselman, David H. Lawson, Jane F. Gumnick et al. · 2001 · New England Journal of Medicine · 1.1K citations
In patients with malignant melanoma, pretreatment with paroxetine appears to be an effective strategy for minimizing depression induced by interferon alfa.
Reading Guide
Foundational Papers
Start with Langley et al. (2005) for DLQI in psoriasis epidemiology; Nestlé et al. (2009) for clinical context (2693 citations); Langley et al. (2014) for trial applications.
Recent Advances
Kong et al. (2012) for microbiome-QoL links; Castro et al. (2018) and Rabe et al. (2018) extend to asthma parallels adaptable to skin diseases.
Core Methods
DLQI scoring: sum 10 items (3 points max each); bands: 0-1=no effect, 21-30=extremely large. Psychometrics via test-retest, MCID=3.5 points; applied in RCTs with secukinumab (Langley et al., 2014).
How PapersFlow Helps You Research Dermatology Life Quality Index
Discover & Search
Research Agent uses searchPapers and citationGraph to map DLQI applications from Langley et al. (2005) (1086 citations), revealing clusters in psoriasis trials. exaSearch finds derivatives; findSimilarPapers links to Kong et al. (2012) for atopic dermatitis QoL.
Analyze & Verify
Analysis Agent applies readPaperContent to extract DLQI scoring from Langley et al. (2014), then verifyResponse with CoVe checks trial claims against raw data. runPythonAnalysis computes score distributions from supplementary tables, with GRADE grading for outcome reliability.
Synthesize & Write
Synthesis Agent detects gaps in DLQI validation via contradiction flagging across papers. Writing Agent uses latexEditText for QoL sections, latexSyncCitations for 20+ references, and latexCompile for trial reports; exportMermaid diagrams DLQI domains.
Use Cases
"Run statistical analysis on DLQI score changes in secukinumab psoriasis trials."
Research Agent → searchPapers('DLQI secukinumab') → Analysis Agent → readPaperContent(Langley 2014) → runPythonAnalysis(pandas on supplementary data) → matplotlib plots of mean DLQI reductions.
"Draft LaTeX review on DLQI in atopic dermatitis with citations."
Synthesis Agent → gap detection(DLQI atopic) → Writing Agent → latexEditText(structured review) → latexSyncCitations(10 papers) → latexCompile(PDF) → researcher gets formatted manuscript.
"Find code for DLQI validation analysis from related papers."
Research Agent → paperExtractUrls(Kong 2012) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow → researcher gets R scripts for DLQI psychometric analysis.
Automated Workflows
Deep Research workflow scans 50+ DLQI papers via citationGraph, generating structured reports on validation across diseases. DeepScan applies 7-step analysis to Langley et al. (2005), with CoVe checkpoints verifying QoL epidemiology. Theorizer builds hypotheses linking DLQI to microbiome data from Kong et al. (2012).
Frequently Asked Questions
What is the DLQI definition?
DLQI is a 10-item, self-administered questionnaire scoring skin disease impact on quality of life from 0 (no impact) to 30 (maximum impact), validated in 1994.
What methods validate DLQI?
DLQI uses Likert scales across 6 domains: symptoms, embarrassment, daily activities, personal relationships, sport, and treatment. Reliability tested via Cronbach's alpha >0.85; responsiveness in trials like Langley et al. (2014).
What are key DLQI papers?
Langley et al. (2005) reviews psoriasis QoL (1086 citations); Langley et al. (2014) shows secukinumab effects (1917 citations); Kong et al. (2012) links to atopic dermatitis microbiome (1723 citations).
What are open problems in DLQI research?
Challenges include pediatric versions, digital adaptations, and integration with biomarkers. Longitudinal sensitivity and cross-cultural equivalence need addressing (Asher et al., 1995).
Research Dermatology and Skin Diseases with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Dermatology Life Quality Index with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Dermatology and Skin Diseases Research Guide